Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Abbreviations: 1H MRS, proton magnetic resonance spectroscopy; AO, adverse outcome; AMD, peptidyl-glycine α-amidating monooxygenase; BDNF, brain-derived neurotrophic factor; CHSTC; carbohydrate sulfotransferase 12; Cr, creatine; DCLK3, doublecortin like kinase 3; ELISA, Enzyme-linked immunosorbent assay; EBM, effect biomarker; FURIN, furin; GABA, gamma-aminobutyric acid; Glc, Glucose; Glx, glutamate; GWAS, Genome-wide association study; HTR6, 5-hydroxytryptamine receptor 6; HXK2, hexokinase 2; Insr, Insulin receptor; MCHR1, melanin concentrating hormone receptor 1; MMP-2, matrix metalloproteinase- 2; MMP9, matrix metalloproteinase- 9; NCF-1, neutrophil cytosol factor 1; Nfkb, nuclear factor kappa B; NGAL, neutrophil gelatinaseassociated lipocalin; Parp1, poly (ADP-ribose) polymerase 1; PCr, phosphocreatine; PET, positron emission tomography; qPCR, quantitative polymerase chain reaction; SLIT2, slit homologue 2 protein; SPD, Protein levels of protein D; Tau, taurine; t-tau, total taurine; TWAS, transcriptome-wide association study; VEGF, vascular endothelial growth factor; VEGFR1, Vascular endothelial growth factor receptor 1; Vit D, 25-hydroxyvitamin-D (25(OH)D).
Source: Reduced levels brain-derived neurotrophic factor (BDNF) and function of the neurons related to impaired learning and memory. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Epidemiological relevant effect biomarkers for thyroid hormone system related adverse outcome pathways: a literature review
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Epidemiological relevant effect biomarkers for thyroid hormone system related adverse outcome pathways: a literature review
Review / evidence synthesis · Frontiers in Pharmacology · 2026
Original publication title
Epidemiological relevant effect biomarkers for thyroid hormone system related adverse outcome pathways: a literature review
Copyright © 2026 Wielsøe, Long, Stratidakis, Renieri, Sarigiannis and Bonefeld-Jørgensen.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This review aims to identify and evaluate effect biomarkers for thyroid hormone system-related AOPs for further validation in experimental and epidemiological studies.
Source: AimAbstract: What methods does the paper describe?
Using AOP-wiki, we extracted and analysed thyroid-related AOPs, focusing on the eleven AOPs with mammalian evidence. We did systematic literature search to identify potential effect biomarkers for future epidemiological studies.
Source: MethodsAbstract: Results
In an AOP network analysis of the eleven thyroid-related AOPs, we identified four AOP clusters, including hippocampal alterations, impaired learning and memory, thyroid follicular cell adenomas/carcinomas, and kidney toxicity. For the clusters on hippocampal alterations and impaired learning and memory, brain-derived neurotrophic factor emerged as a promising effect biomarker. For the cluster on thyroid follicular cell adenomas/carcinomas, no promising effect biomarkers with high specificity were identified, but interleukin-34, oxidative stress, and expression of several genes were found to be related to the adverse outcome.
For kidney toxicity, a panel of effect biomarkers were identified, such as clusterin, cystatin-C, kidney injury molecule-1, N-acetyl-beta-d-glucosaminidase, neutrophil gelatinase-associated lipocalin, and osteopontin.
Source: ResultsAbstract: Conclusion
This review operationalizes the AOP framework to support the use of mechanistically anchored effect biomarkers in human studies on THSD. By aligning key biological events with measurable endpoints, human matrices, and feasibility considerations, it provides a scientifically grounded path from mechanistic understanding to population research application. This enables more targeted biomonitoring, strengthens interpretation of epidemiological findings, and informs research and regulatory priorities for future validation efforts.
Source: ConclusionAuthors’ abstract
Background
Many factors, such as lifestyle, medication, and environmental exposures, are reported to cause thyroid hormone system disruption (THSD) in humans, however studies linking THSD to health effects are sparse. Adverse Outcome Pathways (AOPs) provide mechanistic links from molecular events to adverse outcomes, with effect biomarkers serving as a tool to empirically anchor key events and health effects and to assess biological relevance.
Aim
This review aims to identify and evaluate effect biomarkers for thyroid hormone system-related AOPs for further validation in experimental and epidemiological studies.
Methods
Using AOP-wiki, we extracted and analysed thyroid-related AOPs, focusing on the eleven AOPs with mammalian evidence. We did systematic literature search to identify potential effect biomarkers for future epidemiological studies.
Results
In an AOP network analysis of the eleven thyroid-related AOPs, we identified four AOP clusters, including hippocampal alterations, impaired learning and memory, thyroid follicular cell adenomas/carcinomas, and kidney toxicity. For the clusters on hippocampal alterations and impaired learning and memory, brain-derived neurotrophic factor emerged as a promising effect biomarker. For the cluster on thyroid follicular cell adenomas/carcinomas, no promising effect biomarkers with high specificity were identified, but interleukin-34, oxidative stress, and expression of several genes were found to be related to the adverse outcome.
For kidney toxicity, a panel of effect biomarkers were identified, such as clusterin, cystatin-C, kidney injury molecule-1, N-acetyl-beta-d-glucosaminidase, neutrophil gelatinase-associated lipocalin, and osteopontin.
Conclusion
This review operationalizes the AOP framework to support the use of mechanistically anchored effect biomarkers in human studies on THSD. By aligning key biological events with measurable endpoints, human matrices, and feasibility considerations, it provides a scientifically grounded path from mechanistic understanding to population research application. This enables more targeted biomonitoring, strengthens interpretation of epidemiological findings, and informs research and regulatory priorities for future validation efforts.
Publication and source details
Original title: Epidemiological relevant effect biomarkers for thyroid hormone system related adverse outcome pathways: a literature review
Maria Wielsøe; Manhai Long; Antonios K. Stratidakis; Elisavet Renieri; Dimosthenis A. Sarigiannis; Eva Cecilie Bonefeld-Jørgensen
Frontiers in Pharmacology · 2026
* Correspondence: Eva Cecilie Bonefeld-Jørgensen, ebj@ph.au.dk Copyright © 2026 Wielsøe, Long, Stratidakis, Renieri, Sarigiannis and Bonefeld-Jørgensen.2026Wielsøe, Long, Stratidakis, Renieri, Sarigiannis and Bonefeld-Jørgensenhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. HORIZON EUROPE Framework Programme10.13039/100018693 The author(s) declared that financial support was received for this work and/or its publication. This work was carried out in the framework of the European Partnership for the Assessment of Risks from Chemicals (PARC) and has received funding from the European Union’s Horizon Europe research and innovation programme under Grant Agreement No 101057014. Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:49:32.295345+00:00
DOI: 10.3389/fphar.2026.1760820 · PMC12996058